Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01147250 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
A Phase 3 study of Acute Coronary Syndrome, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,068
- Enrollment target
- 20
- Study locations
NCT01147250 is a Phase 3 study of Acute Coronary Syndrome that has completed, run by Sanofi. The registered enrollment target is 6,068 participants, above the 2,570-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (136% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT01147250, a Phase 3 study of Acute Coronary Syndrome, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,068 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objective: \- To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina) compared to placebo in type 2 diabetic participants who recently experienced an acute coronary syndrome (ACS) event. Secondary Objectives: To demonstrate that when compared to placebo, lixisenatide can reduce: * composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, or hospitalization for heart failure. * composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, hospitalization for heart failure, or coronary revascularization procedure. * urinary albumin excretion (based on the urinary albumin/creatinine ratio). To assess the safety and tolerability of lixisenatide.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lixisenatide (AVE0010)
Study Locations (20)
Alabama
- Investigational Site Number 840415 - Birmingham
- Investigational Site Number 840307 - Foley
- Investigational Site Number 840692 - Mobile
- Investigational Site Number 840037 - Mobile
- Investigational Site Number 840210 - Mobile
- Investigational Site Number 840326 - Muscle Shoals
- Investigational Site Number 840393 - Toney
Arizona
- Investigational Site Number 840656 - Mesa
- Investigational Site Number 840506 - Phoenix
- Investigational Site Number 840520 - Phoenix
- Investigational Site Number 840322 - Phoenix
- Investigational Site Number 840250 - Tempe
- Investigational Site Number 840042 - Tucson
Arkansas
- Investigational Site Number 840303 - Hot Springs
- Investigational Site Number 840184 - Jonesboro
- Investigational Site Number 840361 - Little Rock
- Investigational Site Number 840023 - Little Rock
California
- Investigational Site Number 840706 - Anaheim
- Investigational Site Number 840497 - Anaheim
- Investigational Site Number 840667 - Downey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,068 participants |
| Start Date | 2010-06 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01147250
The ClinicalTrials.gov registry entry for NCT01147250 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 6,068 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,570-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (136% higher). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01147250 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alabama, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT01147250 about?
NCT01147250 is a clinical study titled "Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)". Primary Objective: \- To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina) compared to placebo in type 2 diabetic participants who recentl...
What is the current status of trial NCT01147250?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,068 participants. The study started on 2010-06. Estimated completion is 2015-02.
What conditions does trial NCT01147250 study?
This clinical trial studies the following conditions: Acute Coronary Syndrome.
What interventions are being tested in trial NCT01147250?
The interventions under investigation include: Placebo (DRUG), Lixisenatide (AVE0010) (DRUG).
Who is sponsoring clinical trial NCT01147250?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01147250 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Coronary Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
RECRUITING · Phase 3
-
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
COMPLETED · Phase 3
-
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
COMPLETED · Phase 3
-
Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome
COMPLETED · Phase 3
-
A Polypill for Acute Coronary Syndrome
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.